



Distribuito in ITALIA da  
**Li StarFish S.r.l.**  
Via Cavour, 35  
20063 Cernusco S/N (MI)  
telefono 02-92150794  
info@listarfish.it  
www.listarfish.it


**Manual**

## **ID-Vit<sup>®</sup> folic acid**

***Microbiological test kit for the determination of folic acid in  
serum using a Lactobacillus rhamnosus coated  
microtitre plate  
For use in human and veterinary medicine and in research***

Valid from 2019-05-23

**REF** KIF005



**IVD** **CE**



**Immundiagnostik AG**, Stubenwald-Allee 8a, 64625 Bensheim, Germany

Tel.: +49 6251 70190-0

Fax: + 49 6251 70190-363

e.mail: info@immundiagnostik.com www.immundiagnostik.com

# Table of Contents

<b>1. INTENDED USE</b>	<b>17</b>
<b>2. INTRODUCTION</b>	<b>17</b>
<b>3. PRINCIPLE OF THE TEST</b>	<b>18</b>
<b>4. MATERIAL SUPPLIED</b>	<b>19</b>
<b>5. MATERIAL REQUIRED BUT NOT SUPPLIED</b>	<b>19</b>
<b>6. PRECAUTIONS</b>	<b>19</b>
<b>7. STORAGE AND PREPARATION OF REAGENTS</b>	<b>20</b>
7.1 Water	20
7.2 Preparation of the controls	20
7.3 Preparation of the standard curve	21
7.4 Preparation of the sterile assay medium	21
7.5 Microtiter plate [PLATE]	22
<b>8. SAMPLE STORAGE AND PREPARATION</b>	<b>22</b>
8.1 Sample pretreatment	22
8.2 Sample dilution	22
<b>9. ASSAY PROCEDURE</b>	<b>23</b>
9.1 Test preparations	23
9.2 Test procedure	23
9.3 Measurement	23
<b>10. EVALUATION OF RESULTS</b>	<b>24</b>
10.1 Calculation	24
10.2 Quality control	24
<b>11. LIMITATIONS</b>	<b>24</b>
<b>12. PERFORMANCE CHARACTERISTICS</b>	<b>24</b>
12.1 Precision and reproducibility	25
12.2 Recovery	25
12.3 Linearity	26
<b>13. REFERENCES</b>	<b>27</b>
<b>14. GENERAL NOTES ON THE TEST AND TEST PROCEDURE</b>	<b>27</b>

## 1. INTENDED USE

ID-Vit® Folic acid is a microtiter plate test kit based on a microbiological method which measures the total folic acid content in serum. The test kit contains the standard and all reagents required to perform the test. It is sufficient for 96 determinations including standard curves. An ELISA reader is required for the evaluation of the results. For use in human and veterinary medicine and in research. For *in vitro* diagnostic use only.

## 2. INTRODUCTION

Folic acid, a water soluble, light and temperature sensitive vitamin of the B complex (vitamin B<sub>9</sub>), is involved in all growth and development processes of the body. Folic acid is essential for the formation of red blood cells, for optimal functioning of the bone marrow and for healthy nerve activity. Moreover, folic acid is essential for cell division, therefore it is important in foetus development.

Although most plant and animal based foods contain folic acid, a deficiency of folic acid is the most widespread vitamin deficiency in Europe and North America. According to information from the German Nutritional Society (Deutschen Gesellschaft für Ernährung) only one in four Germans absorb sufficient folic acid – the result of one-sided nutritional habits with little fresh fruit and vegetables. But also age, disease and the influence of specific medications, e. g. cotrimoxazol, may lead to resorption disturbances and to an associated deficiency.

Lowered folic acid levels occur because of:

- a decreased supply (e. g. through alcoholism or folic acid antagonists),
- a disrupted resorption (e. g. in celiac disease, CED),
- an increased requirement (e. g. during pregnancy, in anaemic or cancerous diseases).

### Symptoms of Deficiency

The first symptoms of deficiency are weariness, irritability, concentration problems and loss of appetite; further consequences are inflammation of the mucous membranes, anaemia and grievous neurological damage.

During pregnancy, when the folic acid requirements are doubled, a deficiency in folic acid may lead to premature birth and severe abnormalities. An optimal supplementation of folic acid during the pregnancy can reduce the risk of neural tube defects in the foetus by 85%.

Because a deficiency of either vitamin B<sub>12</sub> or folic acid may lead to megaloblastic anaemia, the determination of both vitamins is important for the clinical picture so that the correct vitamin may be supplemented. Otherwise, in the case of vitamin B<sub>12</sub>

deficiency, treatment of megaloblastic anaemia with folic acid may lead to irreversible damage of the central nervous system.

### **Folic acid and arteriosclerosis**

A folic acid deficiency is known to be the most common cause of hyperhomocysteinaemia. Meanwhile, the hyperhomocysteinaemia has been recognised as an independent factor in arteriosclerosis. Therefore, the determination of folic acid can be carried out within the framework of a coronary disease risk analysis. Beside of the influence of folic acid on the homocysteine levels, a further positive effect on the endothelial function in heart patients has been established – development of nitrate tolerance during continuous nitrate therapy, e.g. in such patients, an increased release of oxygen radicals occurs without folic acid supplementation (Verhaar et al. 2002).

### **Indications**

- Hyperchrome, macrocytic anemia
- Long-term therapy with antiepileptic drugs or folic acid antagonists
- Long-term haemodialysis
- Multiple birth pregnancy/planned pregnancy
- Enhanced erythropoiesis
- Chronic liver diseases
- Hemoblastosis
- Psoriasis, dermatitis
- Stomatitis, glossitis
- Chronic alcohol abus

## **3. PRINCIPLE OF THE TEST**

The serum samples are pre-treated and diluted with a buffer mixture, and then transferred into the wells of a microtiter plate coated with *Lactobacillus rhamnosus*. The addition of folic acid in either standards or samples gives a folic acid-dependent growth response until folic acid is consumed. After incubation at **37 °C** for **48 h**, the growth of *Lactobacillus rhamnosus* is measured turbidimetrically at 610–630 nm (alternatively at 540–550 nm) in an ELISA reader and compared to a standard curve generated from the dilution series. The amount of folic acid is directly proportional to the turbidity.

#### 4. MATERIAL SUPPLIED

Cat. No.	Label	Kit components	Quantity
KIF005	PLATE	<i>Lactobacillus rhamnosus</i> -precoated microtiter plate	1 x
KIF005	SOL	Sample treatment solution	4 x 5 ml
KIF005	DIL	Water	4 x 30 ml
KIF005	ASYMED	Folic acid assay medium	4 x
KIF005	STD	Folic acid standard, lyoph.	4 x
KIF005	FOL	Adhesive cover foil	4 x
KIF005	FRA	Replacement holder for microtiter strips	1 x
KIF005	ASYBUF	Folic acid medium treatment buffer	4 x 1.5 ml
KIF005	CTRL1	Folic acid control 1, lyoph.	4 x
KIF005	CTRL2	Folic acid control 2, lyoph.	4 x

#### 5. MATERIAL REQUIRED BUT NOT SUPPLIED

- Incubator with a dark incubation chamber, 37 °C
- Water bath (90 °C–100 °C)
- optional for sample preparation: themoblock (95 °C)
- ELISA reader 610–630 nm (540–550 nm)
- Calibrated precision pipettors and sterile 20–1000 µl tips
- 5 ml and 10 ml pipets
- 1.5–2 ml reaction vials, sterile
- 0.2 µm sterile polyethersulfone (PES) filter with a sterile disposable syringe
- 15 ml centrifuge tubes, sterile (e.g. Falcon tubes)
- Biocentrifuge (10 000 g)

#### 6. PRECAUTIONS

- As the test is based on a microbiological method, the general guidelines for sterile work should be observed as far as possible (preferably work in a sterile bench / PCR hood, use of sterile instruments or equipment).
- GLP (Good Laboratory Practice) guidelines have to be observed.

- Water quality is extremely important for the test. Only the water delivered with the test kit [DIL] should be used.
- For sterile filtration, only a sterile polyethersulfone filter must be used.
- It is essential to run a standard curve for each separate assay.
- Controls should be measured with each assay.
- We recommend measurements in duplicate.
- If a higher dilution results in a higher value measured, inhibitors like antibiotics might be present.
- Reagents should not be used beyond the expiration date shown on the label.
- Wear gloves during the test.
- Used microtiter stripes [PLATE] and materials that have been in contact with patient samples should be handled and disposed as potentially infectious.

## 7. STORAGE AND PREPARATION OF REAGENTS

- Store test kit and reagents at 2–8 °C.
- Prepare reagents freshly and use them immediately after preparation. Discard remaining unused reagents and waste in accordance with country, federal, state, and local regulations.
- To run the assay more than once, ensure that reagents are stored at the conditions stated on the label. Prepare only the appropriate amount necessary for each run. The kit can be used up to 4 times within the expiry date stated on the label.

### 7.1 Water

- Water [DIL] (for medium [ASYMED], standard [STD] and controls [CTRL1, CTRL2])
- Push the lid up and pull it back to the rim of the glass, then twist the whole cap off.

### 7.2 Preparation of the controls

- The lyophilised controls [CTRL1, CTRL2] have to be resuspended with each 125 µl water [DIL] from the test kit, then homogenise using a vortex.

- After reconstitution, the controls are treated like samples.
- The concentration of the controls changes from lot to lot and is stated in the product specification.

### 7.3 Preparation of the standard curve

- For the preparation of the standard curve, standard concentrate is needed. To prepare standard concentrate, resuspend the lyophilised standard [STD] with x ml (x = please see the enclosed quality control protocol for the volume needed) water [DIL] supplied with the test kit, then homogenise using a vortex.
- Prepare a standard curve in 6 sterile reaction tubes (1.5–2 ml volume) from standard concentrate and water [DIL] following the scheme depicted in the table below:

<b>Folic acid [µg/l]</b>	<b>Water [DIL] [µl]</b>	<b>+</b>	<b>Standard concentrate [µl]</b>	<b>=</b>	<b>Total volume [µl]</b>
Blank: 0	450	+	0	=	450
Standard 1: 0.04	450	+	50	=	500
Standard 2: 0.08	400	+	100	=	500
Standard 3: 0.16	300	+	200	=	500
Standard 4: 0.24	200	+	300	=	500
Standard 5: 0.32	100	+	400	=	500

### 7.4 Preparation of the sterile assay medium

- Fresh sterile assay medium has to be prepared each time before performing a test.
- Remove lyophilised assay medium from the desiccant bag in the assay medium bottle by taking the bag with a forceps and shaking it whilst still inside the bottle. Then remove the clean desiccant bag and discard it.
- Add 10 ml water [DIL] and 1 ml medium treatment buffer [ASYMED] to the assay medium bottle [ASYMED], close the bottle firmly and shake it. This amount is sufficient for 6 microtiter stripes.
- Heat the medium bottle in a water bath at 90–100 °C for 5 min, shake well at least 2 times during this incubation time. Take care that the medium bottle is always firmly closed.

- Quickly cool the medium bottle to  $< 30^{\circ}\text{C}$  (at  $2-8^{\circ}\text{C}$  for 10 min).
- Filter the medium using a disposable syringe (10 ml) and the  $0.2\ \mu\text{m}$  PES filter into a sterile centrifuge tube (15 ml, e. g. Falcon).
- After this preparation, the sterile assay medium can be used in the test.

### 7.5 Microtiter plate [PLATE]

- Store the microtiter plate [PLATE] in the aluminium packaging containing the desiccant bag at  $2-8^{\circ}\text{C}$ .
- The microtiter plate [PLATE] has to be protected from humidity and contamination.
- Take care that the aluminium packaging is not damaged.
- Carefully close the aluminium packaging after opening.
- Take only the microtiter stripes needed directly before usage to avoid contamination

## 8. SAMPLE STORAGE AND PREPARATION

- Use serum for analysis.
- Samples are stable at  $2-8^{\circ}\text{C}$  for 8 hours in the dark. For longer storage, samples should be frozen and kept at  $-20^{\circ}\text{C}$ .
- Hemolytic samples may give erroneous results and should not be used for analysis. Lipemic samples should be centrifuged at  $13\ 000g$  before assaying to obtain fat free serum as far as possible.
- Samples should be centrifuged (at least 5 min at  $10\ 000g$ ) prior to measurement. Use the resulting supernatant in the test.

### 8.1 Sample pretreatment

Add  $100\ \mu\text{l}$  serum/control to  $400\ \mu\text{l}$  of sample treatment solution [SOL] (ratio 1:5), mix. Then heat to  $95^{\circ}\text{C}$  for 30 min, cool quickly (at  $2-8^{\circ}\text{C}$  for 10 min) and centrifuge for 10 min at  $10\ 000g$ .

### 8.2 Sample dilution

Take  $50\ \mu\text{l}$  from the supernatant of the treated sample/control, add  $700\ \mu\text{l}$  water [DIL] and mix. The sample treatment and dilution result in a total dilution of 1:75 (= sample dilution factor).



## 9. ASSAY PROCEDURE

### 9.1 Test preparations

Take as many microtiter strips as needed from kit. Return unused strips and any unused test kit component to the original packaging, and put in the refrigerator. Bring all necessary reagents to room temperature.

### 9.2 Test procedure

- Take as many microtiter strips as needed from the kit and put them in the second microtiter strip holder [FRA].
- Put 150 µl sterile assay medium into the cavities.
- Add each 150 µl of the prepared standard curve, samples and controls into the respective cavities. Pre-rinse each pipet tip with standard, control or sample solution, respectively.
- Carefully seal the plate with adhesive cover foil [FOL]. Important: the cavities must be made airtight by pressing the foil down with the hand!
- Keep at 37 °C for 48 h in an incubator.

### 9.3 Measurement

- Press the adhesive cover foil [FOL] firmly down again with the hand.
- Upturn the microtiter plate [PLATE], put it onto a tabletop and shake the microbes well.
- Turn the microtiter plate [PLATE] over again and carefully remove the adhesive cover foil [FOL]. During this, fix the strips in the frame with your hand because the foil is highly adhesive.
- Remove air bubbles in the cavities using a pipet tip or a needle.
- Read turbidity in an ELISA reader at E 610–630 nm (alternatively at E 540–550 nm).

#### Please note

- After 48 h incubation time, the microtiter plate [PLATE] may be stored for a maximum of 48 h in the refrigerator before measuring the turbidity.
- To prevent time-loss through public holidays or weekends, the microtiter plate [PLATE] may also be evaluated after 60 h incubation.

## 10. EVALUATION OF RESULTS

We recommend to use the 4 parameter algorithm to calculate the results. The sample dilution factor has to be considered for data evaluation.

The blank should have an optical density < standard 1. It serves as optical control to exclude contaminations and is not included in the calculation of results.

### 10.1 Calculation

Folic acid in  $\mu\text{g/l}$  = value from the standard curve  $\times$  sample dilution factor (75)

#### Reference value for human serum

Based on studies of serum samples of apparently healthy persons ( $n = 74$ ), the following values were estimated.

Folic acid: 3.8–23.2  $\mu\text{g/l}$

#### Please note

A concentration range of 3–24  $\mu\text{g/l}$  folic acid is covered at a sample dilution of 1:75.

We recommend each laboratory to develop its own normal range as normal ranges strongly depend on the choice of the patient collective. The values mentioned above are only for orientation and can deviate from other published data.

### 10.2 Quality control

The extinction of the highest standard has to be  $> 0.6$ .

Results, generated from the analysis of control samples, should be evaluated for acceptability. The results for the samples may not be valid if within the same assay one or more values of the quality control sample or the highest standard are outside the acceptable limits.

## 11. LIMITATIONS

Whole blood cannot be used in the assay.

## 12. PERFORMANCE CHARACTERISTICS

The following performance characteristics have been collected using human serum samples.

### 12.1 Precision and reproducibility

#### Intraassay (n = 21)

	Folic acid [ $\mu\text{g/l}$ ]	CV [%]
Sample	12.69	4.7

#### Interassay (n = 3)

	Folic acid [ $\mu\text{g/l}$ ]	CV [%]
Sample	12.24	5.68

### 12.2 Recovery

Samples from 4 patients were differently diluted (75, 150, 300), spiked with folic acid and analysed. The mean values are shown below.

Sample (n=9)	Mean value original sample [ $\mu\text{g/l}$ ]	Spike [ $\mu\text{g/l}$ ]	Folic acid expected [ $\mu\text{g/l}$ ]	Folic acid measured [ $\mu\text{g/l}$ ]	Recovery Rate [%]
A	8.2	5	13.2	13.8	112
		10	18.2	19.1	109
		15	23.2	24.8	111
<b>Recovery rate in total [%]</b>					<b>111</b>

Sample (n=8)	Mean value original sample [ $\mu\text{g/l}$ ]	Spike [ $\mu\text{g/l}$ ]	Folic acid expected [ $\mu\text{g/l}$ ]	Folic acid measured [ $\mu\text{g/l}$ ]	Recovery Rate [%]
B	3.9	5	8.9	9.3	108
		10	13.9	14.3	104
		15	18.9	19.5	104
<b>Recovery rate in total [%]</b>					<b>105</b>

Sample (n=8)	Mean value original sample [µg/l]	Spike [µg/l]	Folic acid expected [µg/l]	Folic acid measured [µg/l]	Recovery Rate [%]
C	4.4	5	9.4	9.6	104
		10	14.4	14.5	101
		15	19.4	20.0	104
<b>Recovery rate in total [%]</b>					<b>103</b>

Sample (n=8)	Mean value original sample [µg/l]	Spike [µg/l]	Folic acid expected [µg/l]	Folic acid measured [µg/l]	Recovery Rate [%]
D	5.1	5	10.1	10.6	110
		10	15.1	15.3	102
		15	20.1	20.6	103
<b>Recovery rate in total [%]</b>					<b>105</b>

### 12.3 Linearity

Samples from 2 patients were diluted and analysed. The results are shown below.

Sample	Dilution	Folic acid expected [µg/l]	Folic acid detected [µg/l]
A	75	13.2	13.7
	150		14.0
	300		13.9
C	150	19.4	20.1
	300		20.7
	150		19.4












### 13. REFERENCES

1. Obeid, R. & Herrmann, W., 2006. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. *FEBS letters*, **580**(13), pp.2994–3005.
2. Strohecker, R. & Henning, H., 1963. Vitamin-Bestimmungen. Erprobte Methoden. E. Merck AG, ed., Weinheim/Bergstraße: Verlag Chemie GmbH.
3. Verhaar, M.C., Stroes, E. & Rabelink, T.J., 2002. Folates and cardiovascular disease. *Arteriosclerosis, thrombosis, and vascular biology*, **22**(1), pp.6–13.

### 14. GENERAL NOTES ON THE TEST AND TEST PROCEDURE

- This assay was produced and distributed according to the IVD guidelines of 98/79/EC.
- All reagents in the kit package are for *in vitro* diagnostic use only.
- ID-Vit® is a trademark of Immundiagnostik AG.
- Reagents should not be used beyond the expiration date stated on the kit label.
- Do not interchange different lot numbers of any kit component within the same assay.
- The guidelines for medical laboratories should be followed.
- Incubation time, incubation temperature and pipetting volumes of the components are defined by the producer. Any variation of the test procedure, which is not coordinated with the producer, may influence the results of the test. Immundiagnostik AG can therefore not be held responsible for any damage resulting from incorrect use.
- Warranty claims and complaints regarding deficiencies must be logged within 14 days after receipt of the product. The product should be send to Immundiagnostik AG along with a written complaint.
- Control samples should be analysed with each run.
- The assay should always be performed according to the enclosed manual.

**Used symbols:**

	Temperature limitation		Catalogue Number
	In Vitro Diagnostic Medical Device		To be used with
	Manufacturer		Contains sufficient for <n> tests
	Lot number		Use by
	Attention		Consult instructions for use
	Consult specification data sheet		